Glenmark Pharmaceuticals vs Strides Pharma Science: Share Price, Comparison and Key Differences

August 10, 2026
Posted by: Kunal Singla
Category: News

Glenmark Pharmaceuticals MCap Rs 64,878 Cr, PE 36.09x, ROE 28.08%, D/E 0.06. Strides Pharma MCap Rs 9,177 Cr, PE 14.46x, ROE 17.90%, D/E 0.57.

Glenmark Pharmaceuticals vs Strides Pharma Science is a comparison mid-cap pharma investors look up when evaluating two listed Indian pharmaceutical companies. Glenmark Pharmaceuticals is known for its branded India dermatology and respiratory franchise, a growing dermatology speciality in the US and its Ichnos Sciences new chemical entity (NCE) pipeline. Strides Pharma Science is a Bengaluru-based specialty pharmaceutical company focused on regulated market generics – particularly injectables for the US, Europe and Australia and institutional antibiotics.

This Glenmark Pharmaceuticals vs Strides Pharma Science article covers reach and market position, key products, latest declared results and stock valuation. The Glenmark Pharmaceuticals vs Strides Pharma Science data below is sourced from Groww and public company filings and reflects the most recently available information at the time of writing.

Table of Contents

Glenmark Pharmaceuticals vs Strides Pharma Science: Reach and Market Position

On the Glenmark Pharmaceuticals side of the Glenmark Pharmaceuticals vs Strides Pharma Science comparison, Glenmark serves India through a large branded field force in dermatology, respiratory, oncology and cardiology, and exports generic and specialty dermatology products to the US and Europe. Market capitalisation is Rs 64,878 Cr.

Click Here – Get Free Investment Predictions

On the Strides Pharma Science side of the Glenmark Pharmaceuticals vs Strides Pharma Science comparison, Strides Pharma serves the US, Europe, Australia and other regulated markets with generic pharmaceuticals including oral solids, softgel capsules and injectables. Market capitalisation is Rs 9,177 Cr.

Glenmark Pharmaceuticals vs Strides Pharma Science: Key Products and Business Mix

In the Glenmark Pharmaceuticals vs Strides Pharma Science product comparison, Glenmark Pharmaceuticals offers: Glenmark earns from India branded generics (La Shield, Candid-B, Telma, Mozobil), US and European generic dermatology and oncology products, and NCE royalties. EPS is Rs 63.71. PE is 36.09x, ROE 28.08 percent, D/E 0.06.

For Strides Pharma Science in this Glenmark Pharmaceuticals vs Strides Pharma Science breakdown: Strides earns from regulated market generic oral and injectable pharmaceuticals, oncology and specialty injectables. EPS is Rs 68.83. PE is 14.46x, ROE 17.90 percent, D/E 0.57.

Glenmark Pharmaceuticals vs Strides Pharma Science: Latest Results

The Glenmark Pharmaceuticals vs Strides Pharma Science results for Glenmark Pharmaceuticals: Glenmark has a market cap of Rs 64,878 Cr and PE of 36.09x. ROE is 28.08 percent – one of the highest in Indian mid-large pharma. Near-zero debt. Glenmark is 7.1 times larger than Strides by market cap.

The Glenmark Pharmaceuticals vs Strides Pharma Science results for Strides Pharma Science: Strides Pharma has a market cap of Rs 9,177 Cr and PE of 14.46x. ROE is 17.90 percent. Strides is significantly cheaper on PE than Glenmark, reflecting its smaller scale and regulated market generic business cyclicality.

Compare Glenmark Pharmaceuticals and Strides Pharma Science Fundamentals on the Univest Screener

Glenmark Pharmaceuticals vs Strides Pharma Science: Stock and Valuation

The Glenmark Pharmaceuticals vs Strides Pharma Science stock comparison uses the latest available market data from Groww. Investors tracking Glenmark Pharmaceuticals vs Strides Pharma Science should verify current prices on NSE or BSE before trading.

Glenmark vs Strides Pharma at current valuations: Glenmark trades at Rs 64,878 Cr market cap, PE 36.09x, ROE 28.08 percent. Strides trades at Rs 9,177 Cr market cap, PE 14.46x, ROE 17.90 percent. Strides is far cheaper on PE but much smaller. Glenmark commands a premium for its India branded franchise and NCE pipeline.

Glenmark Pharmaceuticals vs Strides Pharma Science: Quick Comparison Table

The Glenmark Pharmaceuticals vs Strides Pharma Science comparison table below summarises the key metrics covered in this article side by side.

Parameter	Glenmark Pharmaceuticals	Strides Pharma Science
Sector	India branded + US specialty generics + NCE pipeline	US, EU, Australia generic exports (oral + injectable)
Market Cap	Rs 64,878 Cr	Rs 9,177 Cr
P/E Ratio	36.09x	14.46x
ROE	28.08%	17.90%
Debt to Equity	0.06	0.57
Key Strength	Dermatology branded leadership; NCE pipeline	Regulated market specialty injectables
Dividend	0.11% yield	0.50% yield

Conclusion

The Glenmark Pharmaceuticals vs Strides Pharma Science comparison above covers the key data points on reach, products, results and valuation. Glenmark Pharmaceuticals vs Strides Pharma Science covers two mid pharma companies with very different scale and risk profiles. Glenmark is a mid-large branded Indian pharma with dermatology and respiratory leadership, strong ROE and NCE optionality through Ichnos Sciences. Strides is a pure regulated market generic exporter at a low PE valuation. Glenmark vs Strides investors should review India prescription share, USFDA inspection status, Glenmark NCE data readouts and Strides’s US product pipeline. Glenmark vs Strides Pharma each represent different pharma risk-return – consult a SEBI-registered advisor.

Download the Univest iOS App or Univest Android App to track Glenmark Pharmaceuticals and Strides Pharma Science live price and get daily stock recommendations.

Disclaimer: Data and figures in this article are sourced from publicly available information, including company results filings and exchange data, and are current as of the time of writing. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Frequently Asked Questions

What is Glenmark Pharmaceuticals known for?

Ans. Glenmark is known for its dermatology and respiratory branded franchise in India (La Shield sunscreen, Candid-B antifungal, Teczine antiallergic), a growing US dermatology generics business, and the Ichnos Sciences NCE drug pipeline.

What does Strides Pharma sell?

Ans. Strides Pharma sells generic pharmaceuticals – oral solid dosage forms, softgel capsules, injectables and oncology products – to the US, Europe, Australia and other regulated markets. It also makes bulk antibiotics for institutional markets.

What is Ichnos Sciences?

Ans. Ichnos Sciences is a new chemical entity (NCE) biotech company spun out of Glenmark Pharmaceuticals, developing novel molecules for cancer and autoimmune disease. The NCE pipeline represents long-term upside optionality for Glenmark.

Which is larger, Glenmark or Strides?

Ans. Glenmark Pharmaceuticals at Rs 64,878 Cr is 7.1 times larger than Strides Pharma at Rs 9,177 Cr.

Does Strides Pharma pay dividends?

Ans. Yes. Strides pays a dividend yield of approximately 0.50 percent.

Why is Strides’ PE so low?

Ans. Strides Pharma is a mid-size regulated market generics exporter in a competitive segment. Its lower PE reflects the absence of high-margin India branded business and smaller scale.

Are Glenmark and Strides in Nifty 50?

Ans. Neither is in Nifty 50. Glenmark is tracked in Nifty Pharma; Strides is in broader indices.

News

Author: Kunal Singla

Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.